Montelukast: No Current Use in Asthma

Prescrire International

Volumn 8, Issue 43, 1999, Pages 131-134

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0346452825     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. "Fractures in adults on systemic steroid therapy" see this issue page 153.
2. "Systemic effects of inhaled steroids" Prescr Intern 1995; 4 (17): 83-84.
3. "Drug-induced cataract" Prescr Intern 1994; 3 (11): 79.
4. "Lipomatosis due to chronic steroid therapy" Prescr Intern 1999; 8 (41): 84.
5. Diamant Z et coll. "Effect of oral montelukast (MK-0476), a potent leukotriene receptor antagonist, on allergen-induced airway responses in asthmatic subjects" Am J Respir Crit Care Med 1996; 153 (abstr. A346): 1 page.
6. De Lepeleire I et coll. "Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma" Clin Pharmacol Ther 1997; 61: 83-92.
7. Reiss TF et coll. "MK-0476, an LTD4 receptor antagonist, improves the signs and symptoms of asthma with a dose as low as 10 mg once daily" Am J Respir Crit Care Med 1995; 151 (4) (abstr. A378): 1 page.
8. Bronsky EA et coll. "Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval" Clin Pharmacol Ther 1997; 62: 556-561.
9. Reiss TF et coll. "Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilatation in asthmatic subjects treated with and without inhaled corticosteroids" Thorax 1997;52 : 45-48.
10. Noonan MJ et coll. "Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma" Eur Respir J 1998; 11: 1232-1239.
11. Kuna P et coll. "Montelukast (MK-0476), a cysLT1 receptor antagonist, improves asthma control in aspirin-intolerant asthmatic patients" Am J Respir Crit Care Med 1997; 155 (4 suppl.) (abstr. A975): 1 page.
12. Leff JA et coll. "Montelukast (MK-0476) allows tapering of inhaled corticosteroids (ICS) in asthmatic patients while maintaining clinical stability" Am J Respir Crit Care Med 1997; 155 (4) (abstr. A976): 1 page.
13. Knorr B et coll. "Montelukast for chronic asthma in 6-to 14-year-old children" JAMA 1998; 279 (15): 1181-1186.
14. Reiss TF "Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. A multicenter, randomized, double-blind trial" Arch Intern Med 1998; 158: 1213-1220.
15. Knorr BA et coll. "Montelukast (MK-0476) improves asthma over 6 months of treatment in 6-to 14-year old patients" Eur Respir J 1997; 10 (suppl. 25) (abstr.): 219.
16. Reiss TF et coll. "Montelukast (MK-0476), a cysLT1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment" Eur Respir J 1997; 10 (25 suppl.) (abstr.) : 437.
17. Malmstrom K et coll. "A comparison of montelukast, a leukotriene receptor antagonist, and inhaled beclomethasone in chronic asthma" Eur Respir J 1998; 12 (28 suppl.): 36-37.
18. Kemp JP et coll. "Montelukast once daily inhibits exercise-induced bronchoconstriction in 6-to 14-year-old children with asthma" J Pediatr 1998; 133: 424-428.
19. Leff JA et coll. "Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction" New Engl J Med 1998; 339 (3): 147-152.
20. Villaran C et coll. "Montelukast compared to salmeterol in the treatment of exercise-induced asthma (EIA)" World Asthma Meeting, Barcelone 1998; (abstr. non publié): 1 page.
21. Turpin JA et coll. "Chronic administration of montelukast is superior to inhaled salmeterol in the prevention of exercise-induced bronchoconstriction" Am J Respir Crit Care Med 1998; 157 (part 2) (abstr. A 456): 1 page.
22. Markham A et Faulds D "Montelukast" Drugs 1998; 56 (2): 251-256.
23. French medicines agency "Singulair 10 mg, comprimé pelliculé" SPC, 20 March 1998: 10 pages.
24. French medicines agency "Singulair 5 mg, comprimé à croquer" SPC, 20 March 1998: 10 pages.
25. U.S. Food and Drug Administration "Merck and Co - Dear healthcare professional" December 1998. Site internet de la FDA http://vvwvv.fda.gov consulté le 10 décembre 1998.
26. D'Cruz DP et coll. "Difficult asthma or Churg-Strauss syndrome?" BMJ 1999; 318: 476-477.
27. Reiss TF et coll. "Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma" J Allergy Clin Immunol 1996 ; 98: 528-534.
28. Reiss TF et coll. "Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist" Thorax 1997; 52: 1030-1035.
29. Fauci AS "Allergic angiitis and granulomatosis (Churg-Strauss disease)". In : Fauci AS et coll. "Harrison's principles of internal medicine" 14th ed. McGraw-Hill, New-York 1998: 1914.
30. Horwitz RJ et coll. "The role of leukotriene modifiers in the treatment of asthma" Am J Respir Crit Care Med 1998; 157: 1363-1371.